This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this last chart, we can see the boomerang shift of Americans’ views of the grocery industry in the past few years, from its apex in 2020 in the stay-at-home phase of COVID-19’s publichealth crisis.
Consolidating and coordinating information between providers, payers and publichealth departments is particularly tough, not only because there are so many providers, but because of the variability between data platforms and systems. In recent years, some states leveraged the power of HIEs to identify COVID-19 hotspots in communities.
On March 15, 2022, STAT published text of a proposed compromise at the World Trade Organization (WTO) to temporarily relax global standards for intellectual property for COVID-19. In short, the compromise only waives a single 20-word paragraph in one article: the one dealing with exports under a non-voluntary authorization.
ANVISA published the RDC 702/2022, which repeals some requirements that were instituted to speed market approval of devices needed to treat patients during the height of the COVID-19 pandemic. The Agency recently published the first list of critical medicines for the management of the COVID-19 pandemic.
ANVISA announced major updates to its Resolution of the Collegiate Board of Directors (RDC) 185/2001. 19 Medical Rehabilitation Equipment. It will also facilitate cross-border circulation of these critical health therapies as well as cross-border cooperation between publichealth authorities. CMDE Announcement No.
The early 2020s will be studied by historians as a time of global uncertainty when an unknown pathogen caused a publichealth emergency that brought the world to the brink. So, what other than advances in diagnostic technology, has the experience of Covid given us? Here are just a few examples. Artificial Intelligence .
Commission Extends Transparency and Authorization Mechanism for Exports of COVID-19 Vaccines, 11 March 2021. The EC has extended until the end of June 2021 the transparency and authorization mechanism for COVID-19 vaccine exports. The mechanism provides for authorizations of exports of COVID-19 vaccines outside the EU.
Americans are no doubt conditioned to expect spectacular failure in the face of publichealth crises. The United States had been ravaged for decades by a shape-shifting drug overdose crisis before the emergence of COVID-19. Just as COVID-19 deaths in the U.S. Just as COVID-19 deaths in the U.S.
billion behavioral health contract to Centene Idaho Drops Panel Investigating Pregnancy-Related Deaths as US Maternal Mortality Surges Kootenai Health CEO to retire after nonprofit conversion Kootenai Health on track for nonprofit conversion Ammon Bundy a no-show for beginning of St. How did we get here? to 18 central Mass.
So we do have comments on the bizarre complaint that the Texas attorney general recently filed over COVID-19. The complaint, brought under the Texas consumer protection statute, sued a major manufacturer of COVID-19 vaccine that was used to control the recent pandemic. 247d(a), 247d-6d(a)(1). 247d-6d(a)(2)(A)(i).
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content